20776-61-8

Basic information

• Product Name: 2-AMINO-4,5-DICHLOROBENZOIC ACID
• Synonyms: 2-AMINO-4,5-DICHLOROBENZOIC ACID;3-AMINO-4,5-DICHLOROBENZOIC ACID;4,5-dichloroanthranilic acid;2-aiMo-4,5-dichlorobenzoic acid;2-AMino-4,5-dichlorobenzolc acid;4,5-Dichloro-2-aminobenzoicacid
• CAS NO: 20776-61-8
• Molecular Formula: C₇H₅Cl₂NO₂
• Molecular Weight: 206.03
• Product Categories: Phenylacetic acid
• Mol File: 20776-61-8.mol

Chemical Properties

• Melting Point: 213-214℃
• Boiling Point: 380.503 °C at 760 mmHg
• Flash Point: 183.922 °C
• Appearance: slight yellow crystalline powder
• Density: 1.607±0.06 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.658
• PKA: 4.34±0.10(Predicted)
• CAS DataBase Reference: 2-AMINO-4,5-DICHLOROBENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-AMINO-4,5-DICHLOROBENZOIC ACID(20776-61-8)
• EPA Substance Registry System: 2-AMINO-4,5-DICHLOROBENZOIC ACID(20776-61-8)

Safety Data

• Hazardous Substances Data: 20776-61-8(Hazardous Substances Data)

Usage

Chemical Properties

slight yellow crystalline powder

InChI:InChI=1/C7H5Cl2NO2/c8-4-1-3(7(11)12)6(10)2-5(4)9/h1-2H,10H2,(H,11,12)

Upstream product

• 1677-48-1 5,6-dichloroisatin 
• 214754-55-9 5,6-dichloro-2-hydroxyisoindoline-1,3-dione 
• 50-82-8 2,4,5-trichlorobenzoic acid 
• 7664-41-7 ammonia 
• 6341-92-0 6-chloroisatin 
• 942-06-3 4,5-dichlorophthalic anhydride 
• 5900-58-3 2-amino-4-chloro-benzoic acid methyl ester 
• 844647-17-2 2-amino-4,5-dichloro-benzoic acid methyl ester 
• 6662-53-9 N-(α-Oximino-acetyl)-3.4-dichlor-anilin 

Downstream Products

• 6958-39-0 6,7-dichloroquinazolin-4(3H)-one 
• 113525-09-0 2-(carboxymethyl-amino)-4,5-dichloro-benzoic acid 
• 77423-08-6 2-Amino-4,5-dichloro-benzoic acid hydrazide 
• 887242-92-4 methyl (2S)-{[(2-amino-4,5-dichlorophenyl)carbonyl]amino}(cyclohexyl)-ethanoate 
• 864293-02-7 6,7-dichloroquinazoline-2,4(1H,3H)-dione 
• 844647-17-2 2-amino-4,5-dichloro-benzoic acid methyl ester 
• 1236056-48-6 C₁₄H₈Cl₂N₂O 
• 1297599-49-5 2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichlorobenzoyl chloride 
• 880347-55-7 2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichlorobenzoic acid 
• 1346679-11-5 4,5-dichloro-2-iodobenzoic acid 
• 1346679-13-7 tert-butoxycarbonylmethyl 4,5-dichloro-2-iodobenzoate 
• 1416811-33-0 C₂₁H₂₄Cl₂N₄O₄S 
• 1416811-23-8 C₂₂H₂₂Cl₂N₄O₅S 
• 1416811-21-6 C₂₁H₂₂Cl₂N₄O₃S 

Relevant articles and documents

NOVEL HISTONE METHYLTRANSFERASE INHIBITORS

The present invention relates to novel compounds of formula (I) as defined herein. The compounds are inhibitors of histone methyltransferases of the seven-beta-strand family, in particular of KMT9.

Discovery of novel dual-action antidiabetic agents that inhibit glycogen phosphorylase and activate glucokinase

Dual-target-directed agents simultaneously inhibiting glycogen phosphorylase (GP) and activating glucokinase (GK) could decelerate the inflow of glucose from glycogenolysis and accelerate the outflow of glucose in the liver, therefore allow for a better control over hyperglycaemia in a synergetic manner. A series of hybrid compounds were designed by structure-assisted and ligand-based strategies. In vitro bioassays found two novel compounds (1j, 6g) worthy of further optimization on balance of dual action to GP and GK. In addition, for single-target activity, two compounds exhibited more potent GP inhibitory activity and four compounds showed better GK activation than their corresponding references.

Anthranilic sulfonamide CCK1/CCK2 dual receptor antagonists II: Tuning of receptor selectivity and in vivo efficacy

In the previous article we demonstrated how certain CCK2R-selective anthranilic amides could be structurally modified to afford high-affinity, selective CCK1R activity. We now describe our efforts at modulating and optimizing the CCK1R and CCK2R affinitie

GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF

The invention relates to glycogen phosphorylase inhibitor compounds, pharmaceutical compositions of these compounds, methods of treatment using the pharmaceutical compositions to treat diabetes, conditions associated with diabetes, and/or tissue ischemia,

SULFONAMIDE COMPOUNDS

Certain sulfonamide compounds are dual CCK1/CCK2 inhibitors useful in the treatment of CCK1/CCK2 mediated diseases.

FUSED-RING PYRIMIDIN-4(3H)-ONE DERIVATIVES, PROCESSES FOR THE PREPARATION AND USES THEREOF

AbstractNovel compounds of the following formula (I) and pharmacologically acceptable salt and esters thereof can modulate LXR function and as a result show excellent anti-arteriosclerotic and anti-inflammatory activity:wherein:A represents aryl or heteroaryl;R1, R2 and R3 are the same or different and each represents hydrogen, hydroxyl, nitro, cyano, amino, halogen, carboxy, carbamoyl, mercapto, alkyl, haloalkyl, alkylcarbonyloxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, dialkylamino, alkylcarbonylamino, N-(alkylcarbonyl)-N-(alkyl)amino, alkoxycarbonylamino, N-(alkoxycarbonyl)-N-(alkyl)amino, alkylsulfonylamino, N-(alkylsulfonyl)-N-(alkyl)amino, haloalkylsulfonylamino, N-(haloalkylsulfonyl)-N-(alkyl)amino, alkylcarbonyl, alkoxycarbonyl, alkylaminocarbonyl or dialkylaminocarbonyl group, or R1 and R2 together are alkylenedioxy;R4 and R5 are the same or different and each represents hydrogen, hydroxyl, amino, halogen, mercapto, alkyl, haloalkyl, alkoxy, alkoxycarbonyl or alkylthio;X represents hydrogen, hydroxyl, halogen, alkoxy or haloalkoxy; andY represents an optionally substituted alkyl, cycloalkyl, heterocyclyl, aryl, cycloalkylalkyl, heterocyclylalkyl or aralkyl group.